Short answer
Amylyx Pharmaceuticals, Inc. (AMLX) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$45M
- −32.3% YoY · −4.8% QoQ
- EPS (diluted)
- −$0.39
- −5.4% YoY · +0.0% QoQ
Source: XBRL data from the Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2026 10-Q on SEC EDGAR. USD.
Amylyx Pharmaceuticals, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No quarterly revenue, as Amylyx remained pre-commercial
- Net loss $45.5M vs $34.4M YoY, operating margin not applicable
- R&D $28.4M vs $19.9M, led by avexitide spending of $10.7M
- Cash, equivalents and marketable securities $768.1M, boosted by $544.6M equity proceeds
- Avexitide NDA submission targeted by end-2026, potential commercial launch in 2027 if approved
Risk Factors
- Newly added regulatory risk: 2026 FDA draft guidance and policy reversals may make single-trial approval standards uncertain
- Most materially updated regulatory risk: FDA leadership changes and personnel reductions could delay guidance, reviews, and approvals
- Operational risk: rising GLP-1 demand could constrain peptide-manufacturing capacity and increase avexitide supply costs
- Competitive risk: novel obesity treatments could reduce bariatric surgery and shrink the PBH patient population
- Financial risk: accumulated deficit reached $881.6 million, with no committed source of additional capital
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Amylyx Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.